Please use this identifier to cite or link to this item:
Title: Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease.
Author: Sánchez Ortega, Isabel
Parody, Rocío
Servitje Bedate, Octavio
Muniesa Montserrat, Cristina
Arnan, Montserrat
Patiño, Beatriz
Sureda, Anna
Duarte, Rafael
Keywords: Ús terapèutic
Efectes secundaris dels medicaments
Malalties cròniques
Therapeutic use
Drug side effects
Chronic diseases
Issue Date: 30-Jun-2016
Abstract: Aim To assess the toxicity, tolerance, steroid-sparing capacity, effectiveness, and response rate to imatinib and dasatinib for the treatment of severe sclerotic chronic graft-vs-host disease (scGVHD). Methods This retrospective study analyzed 8 consecutive patients with severe refractory scGVHD who received salvage therapy with imatinib. Patients intolerant and/or refractory to imatinib received dasatinib treatment. Results 7 patients discontinued imatinib treatment (1 achieved complete response, 5 were resistant and/or intolerant, and 1 developed grade IV neutropenia) and 1 patient achieved prolonged partial response, but died due to an infectious complication while on treatment 5 patients started dasatinib treatment (3 achieved partial responses and discontinued dasatinib, 1 achieved a durable partial response, but died due to a consecutive rapid pulmonary cGVHD progression and 1 with stable disease discontinued treatment due to gastroenteric intolerance). The response rate (partial and/or complete responses) for severe scGVHD was 25% for imatinib and 60% for dasatinib. Conclusion In our series, dasatinib was better tolerated, safer, steroid-sparing, and had a low incidence of infectious complications, which suggests that it may be a more effective therapeutic alternative for patients with refractory scGVHD than imatinib. Treatment of scGVHD with effective antifibrotic drugs such as TKI, which block the kinase fibrotic pathway, may be a safe and effective therapeutic option, but further studies are needed to confirm our findings.
Note: Reproducció del document publicat a:
It is part of: Croatian Medical Journal, 2016, vol. 57, num. 3, p. 247-254
Related resource:
ISSN: 0353-9504
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
667006.pdf129.68 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons